Josh Kopelman
Founder and Partner @ First Round Capital
Philadelphia, United States
Josh Kopelman is a Series A investor at First Round Capital in Philadelphia focused on Software and Health Care. Josh Kopelman is the Founder and Partner of First Round Capital. He previously worked at Ed Snider Youth Hockey Foundation as a Member of the Board of Directors. Josh Kopelman attended the Wharton School.
- Total investments:
- 124
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries Josh Kopelman invests in
Stages Josh Kopelman invests in
Countries Josh Kopelman invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $800k–$7.2M
- Series A
- $1.2M–$25M
- Series B
- $7M–$100M
Investment Focus
Industry
- Software 14 (11%)
- Health Care 13 (10%)
- E-Commerce 10 (8%)
- SaaS 9 (7%)
- Internet 9 (7%)
Stage
- Series A 32 (26%)
- Seed 30 (24%)
- Series B 27 (22%)
- Series C 9 (7%)
- Funding Round 6 (5%)
Country
- United States 54 (44%)
- India 1 (1%)
- Israel 1 (1%)
- New Zealand 1 (1%)
- United Kingdom 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Our mission at HealthLeap is to improve global health through better nutrition. We're addressing one of the most significant contributors to global deaths by building a clinical assistant to help healthcare professionals better treat/prevent disease-related malnutrition — the "silent killer" that worsens health outcomes fornearly all sick patients. It is associated with a 3-5x increase in mortality during a hospital stay and affects 30-50% of all hospital patients, but only 5% are diagnosed. | $8M / Seed / Oct 07, 2026 | ||
| Collate creates and streamlines documentation for drug development, medical device, and diagnostic companies from concept to market using artificial intelligence. They produce accurate documentation for the life sciences industry, which speeds up innovations that can save lives. | $95M / Series A / Jun 03, 2026 | ||
| Parallel is a technology company focused on adapting the web for artificial intelligences. It builds retrieval, ranking, and reasoning systems that enable AIs to perform high-value tasks using web data. The company's initial offering is an API designed to facilitate these interactions, enhancing the capabilities of advanced AIs. | $100M / Series B / Apr 28, 2026 | ||
| RenoFi Loans use the after renovation value instead of your home's current value, enabling you to borrow the most money at the lowest rates. RenoFi is not a lender, rather we’ve partnered with lenders who offer RenoFi Loans. These lenders leverage RenoFi's technology platform to seamlessly offer RenoFi Loans. | $22M / Series B / Mar 03, 2026 | ||
| Parallel is a technology company focused on adapting the web for artificial intelligences. It builds retrieval, ranking, and reasoning systems that enable AIs to perform high-value tasks using web data. The company's initial offering is an API designed to facilitate these interactions, enhancing the capabilities of advanced AIs. | $100M / Series A / Nov 12, 2025 | ||
| Collate creates and streamlines documentation for drug development, medical device, and diagnostic companies from concept to market using artificial intelligence. They produce accurate documentation for the life sciences industry, which speeds up innovations that can save lives. | $30M / Seed / Jan 19, 2025 | ||
| Candid Health develops software that supports healthcare organizations in managing revenue cycle operations. Its platform automates and coordinates processes such as medical coding, claims submission, payment posting, denial management, and reimbursement workflows. The company integrates with electronic health record and practice management systemsto facilitate the exchange of clinical and billing data across healthcare providers and payers. It provides tools that enable healthcare organizations to monitor billing performance, identify claim issues, and manage revenue cycle activities through a centralized system. The company also offers analytics and workflow capabilities that support administrative and financial operations within healthcare practices. | $29M / Series B / Sep 11, 2024 | ||
| Vitable Health provides an integrated primary care and urgent care health plan designed for accessibility and affordability. The membership includes virtual and in-home visits, mental health support, and access to free prescriptions. This model empowers employers to enhance their healthcare offerings while reducing costs and improving employeesatisfaction. | $16M / Series A / Jul 19, 2024 | ||
| Pomelo Care is a health technology company that develops evidence-based healthcare solutions for women and children. The company provides a digital care coordination and patient engagement platform designed to support longitudinal care outside traditional clinical settings. Its software connects patients, families, and care teams by centralizingclinical data, care plans, messaging, and care milestones into a single interface that enhances communication and continuity of care. The platform supports workflows across chronic condition management, post-discharge follow-ups, and complex care plans by enabling asynchronous updates, task tracking, assessment collection, and outcome monitoring. Pomelo Care’s tools are used by healthcare providers, care coordinators, and patient support organizations to streamline care delivery, improve engagement, and personalize interventions based on individual patient needs. It also offers integrations with electronic health records and third-party health services to synchronize information flows and reduce administrative burdens. | $46M / Series B / Jun 20, 2024 | ||
| Pomelo Care is a health technology company that develops evidence-based healthcare solutions for women and children. The company provides a digital care coordination and patient engagement platform designed to support longitudinal care outside traditional clinical settings. Its software connects patients, families, and care teams by centralizingclinical data, care plans, messaging, and care milestones into a single interface that enhances communication and continuity of care. The platform supports workflows across chronic condition management, post-discharge follow-ups, and complex care plans by enabling asynchronous updates, task tracking, assessment collection, and outcome monitoring. Pomelo Care’s tools are used by healthcare providers, care coordinators, and patient support organizations to streamline care delivery, improve engagement, and personalize interventions based on individual patient needs. It also offers integrations with electronic health records and third-party health services to synchronize information flows and reduce administrative burdens. | $33M / Series A / Jun 08, 2023 | ||
| See all 124 investments → | |||
Co-Investors
About First Round Capital
First Round is a seed-stage venture firm focused on building a community of technology entrepreneurs and companies, including Uber, Square, and Warby Parker. Through custom-built software, incredible in-person experiences, and a host of other unique services, First Round helps tiny companies get big while constantly reimagining the role of venture capital. It offers a growing number of services and products to help founders build companies from scratch. First Round has adopted the Diversity Term Sheet Rider.
First Round Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amy Fu
VP, Investments
|
|||
Elliot Cohen
Angel Track
|
|||
Emery Rosansky
VP, Revenue Growth and Enablement
|
|||
Akins Van Horne
Angel Track
|
|||
Bill Trenchard
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Josh Kopelman invest in?
Josh Kopelman invests primarily in Software, Health Care and E-Commerce startups, most often at Series A and Seed stage. Most of the 124 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Josh Kopelman invest in?
Josh Kopelman typically joins rounds of $800k–$7.2M at Seed, $1.2M–$25M at Series A and $7M–$100M at Series B. These are whole funding-round sizes, not Josh Kopelman's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Josh Kopelman took part in.
How do I contact Josh Kopelman?
Public channels for Josh Kopelman include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Josh Kopelman last invest?
The most recent investment recorded for Josh Kopelman closed in Oct 2026. Shizune tracks 124 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
